Filing Details
- Accession Number:
- 0001367644-21-000008
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-09 17:23:57
- Reporting Period:
- 2021-02-08
- Accepted Time:
- 2021-02-09 17:23:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1367644 | Emergent Biosolutions Inc. | EBS | Pharmaceutical Preparations (2834) | 141902018 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1380956 | Robert Kramer | 400 Professional Dr, Suite 400 Gaithersburg MD 20879 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-02-08 | 32,397 | $30.86 | 171,607 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-08 | 32,397 | $120.03 | 139,210 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-02-08 | 13,000 | $30.63 | 152,210 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-08 | 13,000 | $120.03 | 139,210 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Options (Right to Buy) | Disposition | 2021-02-08 | 32,397 | $120.03 | 32,397 | $30.86 |
| Common Stock | Employee Stock Options (Right to Buy) | Disposition | 2021-02-08 | 13,000 | $120.03 | 13,000 | $30.63 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2023-02-28 | No | 4 | M | Direct | |
| 19,638 | 2024-02-27 | No | 4 | M | Direct |
Footnotes
- Consists of an option granted on 3/1/2016 under the company's stock incentive plan as amended and restated.
- All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.20.
- Consists of an option granted on 2/28/2017 under the company's stock incentive plan as amended and restated.
- The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.19.
- The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.
Billionaire Hedge Funds
